Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

The government has suggested weight-loss drugs could boost the economy by helping obese people in England get back to work. But NHS experts have warned treatment services are already overstretched trying to deal with unprecedented demand from patients wanting these drugs.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is typically more affordable than Wegovy. At the time of publishing, the list price for Ozempic was $968.52 per month, whereas the list price for Wegovy was $1,349.02 per month. List prices are the price set by the manufacturer.

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on euronews

Weight-loss drugs might help people battle addictions. Alcoholics taking GLP-1 drugs had a 50% lower rate of intoxication. Opioid users taking the drugs had a 40% lower risk of ov

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

Weight loss medications such as Ozempic may be able to cut drug and alcohol misuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found that people who take Ozempic or similar drugs — those used for weight loss or treating Type 2 diabetes — were 40